Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Randomized, 3-Way Crossover Design to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Next Previous
Trial Profile

Open-Label, Randomized, 3-Way Crossover Design to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Breast cancer; Cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 10 Oct 2019 Results of a cross-study analysis of total 7 studies(NCT01703481,NCT02218073,NCT02231489,EuDRACT-2015-001583-19,NCT02692677,NCT03066687and NCT03135106) published in the Journal of Clinical Pharmacology
    • 29 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top